“They found Codivir showing impressive antiviral effect, both in laboratory conditions and in phase 1 clinical trial in humans”, The website Mid East Information wrote about a new drug by Code Pharma.
Code Pharma’s Founder and CEO, Zyon Ayni, quoted in the article: “Codivir showed great success in clinical trials and already has received emergency approvals in different countries for the treatment of coronavirus patients. Our team at Code Pharma are now initiating a multi-country phase 2 study with a larger cohort and has submitted additional emergency approval requests to several affected countries.
Ayni said: “Our phase 1 study with Codivir in Brazil has proven the medication to be safe, and we were able also to demonstrate a reduction in the viral load of the patients during the course of the treatment”.
